Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2020
Pharma News, 2020
WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus
SHANGHAI, China, January 29, 2020–WuXi Biologics (“WuXi Bio”) (2269.
FDA faults Biocon small molecule API facility during preapproval review
The FDA has found a handful of issues with Biocon’s small molecule API facility in Bengaluru, India.
Quality of life extended with atezolizumab and bevacizumab in liver cancer
(HealthDay)—For patients with unresectable hepatocellular carcinoma, the combination of atezolizumab and bevacizumab is associated with longer time to deterioration of patient-reported quali...
Johnson & Johnson ‘pretty confident’ it can develop coronavirus vaccine
Drugmaker Johnson & Johnson is “pretty confident” that it can create a vaccine to combat the deadly coronavirus, an exec said Monday.
FDA Approves Trijardy XR for Type 2 Diabetes in Adults
The U.
Novel molecules display potent and selective action against ovarian tumor cells
A group led by a researcher affiliated with the University of São Paulo's São Carlos Chemistry Institute (IQSC-USP) in Brazil has developed a novel palladium compound that acts against o...
China's coronavirus: rising death toll, global impact
A new virus that China announced in late December has killed more than 100 people, infected more than 4,000 and spread to around 15 countries.
Brilinta hits endpoint in late-stage stroke trial
AstraZeneca has revealed results from its Brilinta (ticagrelor) trial, demonstrating that the drug showed a statistically significant and clinically meaningful reduction in the risk of stroke ...
Success for Enhertu in Phase II gastric cancer trial
Enhertu (trastuzumab deruxtecan) has yielded high-level results from the positive registrational Phase II trial - DESTINY-Gastric01 - AstraZeneca and Daiichi Sankyo have announced.
Krystal Biotech investing up to $90M on facility for its gene therapies
Krystal Biotech is investing $75 million to $100 million on a manufacturing facility that it expects to be ready for the anticipated launch of its first gene therapy.
First human trial of monoclonal antibody to prevent malaria opens
A Phase 1 clinical trial testing the safety and effectiveness of a monoclonal antibody (mAb) against malaria has begun enrolling healthy adult volunteers at the National Institutes of Health C...
U.S. CDC says no new confirmed cases of coronavirus, 110 under investigation
(Reuters) - The U.
66
67
68
69
70
71
72
73
74
